NFHS-6 Health Data: Hospital Revenue Upside, Omission Risk

The sixth edition of the National Family Health Survey (NFHS-6), covering 6.79 lakh households across 715 districts from May 2023 to December 2024, shows broad improvements in India's health metrics. Institutional deliveries rose to 90.6% from 88.6% in NFHS-5 (2019-21). Stunting, wasting, and underweight prevalence among children declined. Breastfeeding and complementary feeding practices improved. These shifts directly affect revenue trajectories for hospitals, insurers, nutrition companies, and diagnostic chains.

The fact sheet omits about 40 indicators that were present in NFHS-5, including anaemia prevalence, clean cooking fuel coverage, sanitation statistics, and mortality data. The government attributes the omissions to methodological changes and duplication with other surveys. For investors, the missing data creates a layer of policy uncertainty that complicates sector-level forecasting.

Why NFHS-6 Data Reshapes Hospital Revenue Projections

Institutional Deliveries and C-Section Rates

Institutional deliveries rose 2 percentage points to 90.6%. That incremental share represents roughly 2.5 million additional births occurring in hospitals rather than at home, based on India's annual birth cohort of about 25 million. Each hospital birth generates revenue from delivery fees, neonatal care, and follow-up consultations.

Key insight: A 2-point gain in institutional deliveries directly expands the addressable market for private hospital chains like Apollo Hospitals and Max Healthcare. The effect compounds when combined with the rise in C-section deliveries from 21.5% to 27.2%. C-sections carry higher procedure fees and longer hospital stays, boosting per-patient revenue.

Child Nutrition and Consumer Staples

Stunting among children under five fell from 35.5% in NFHS-5 to 32.1% in NFHS-6. Wasting dropped from 19.3% to 18.7%. Underweight prevalence declined from 32.1% to 29.1%. These improvements correlate with increased consumption of protein-rich foods, fortified cereals, and nutritional supplements.

Practical rule: Falling stunting rates expand the total addressable market for companies like Nestlé India (nutrition products), Britannia (fortified biscuits), and Hindustan Unilever (health food drinks). The mechanism: healthier children consume more packaged food earlier, and parents spend more on preventive nutrition.

The Nutritional Paradox

Both overweight and underweight prevalence increased among adults. Overweight (BMI ≥25) rose from 24.0% to 26.8% in women and from 22.9% to 25.7% in men. Underweight (BMI <18.5) also increased marginally. This dual trend benefits different sectors: obesity-related healthcare (diabetes, hypertension management) and weight-loss products, while underweight segments sustain demand for calorie-dense staples.

Why This Data Matters Now

Policy Tailwinds for Insurance

Improved health metrics reduce the risk pool for health insurers. Lower stunting and wasting rates mean fewer chronic conditions in the future, potentially lowering claim ratios. The survey's new focus on financial inclusion indicators also aligns with the government's push for Ayushman Bharat expansion and higher insurance penetration.

Risk to watch: The omission of anaemia data is a gap. Anaemia prevalence was 67% in children under five in NFHS-5. Without updated numbers, insurers cannot accurately model maternal and child health claims. The ICMR's separate venous blood survey will fill this gap, timing is uncertain.

Diagnostic Chains and Chronic Disease

NFHS-6 added hypertension and diabetes indicators. The prevalence of hypertension among adults aged 15-49 is 24.0% (up from 21.3% in NFHS-5). Diabetes prevalence rose from 8.6% to 9.8%. These trends directly benefit diagnostic chains like Dr. Lal PathLabs and Metropolis Healthcare, which derive a significant portion of revenue from routine blood tests and chronic disease monitoring.

The Data Omission Risk

Three Categories of Omissions

The fact sheet excludes about 40 indicators from NFHS-5. The government categorises omissions into three groups:

1. Parameters dropped at the questionnaire stage (e.g., anaemia, disability) due to methodological concerns with capillary testing.
2. Parameters tracked through other platforms (clean cooking fuel, sanitation, mortality, birth registration) via Sample Registration System, Civil Registration System, and Census.
3. Indicators to be presented in a detailed report later (family planning, child health interventions, women's health, HIV).

Why Omissions Create Uncertainty

Without anaemia data, investors cannot assess the effectiveness of government iron supplementation programs. Without sanitation and fuel coverage numbers, the impact of Swachh Bharat and Ujjwala schemes on health outcomes remains opaque. The delay in releasing the detailed report – now 18 months after survey completion – raises questions about data quality and political sensitivity.

What this means: Policy-dependent sectors like clean cooking fuel (LPG distributors), sanitation infrastructure (toilet manufacturers), and maternal health programs face delayed visibility. Stocks in these areas may trade on sentiment rather than fundamentals until the full dataset is released.

The Duplication Debate

The government argues that multiple sources enhance verification. Investors lose the ability to cross-check trends across surveys. The Sample Registration System provides mortality data with a 2-3 year lag. The Census, delayed to 2025, adds further uncertainty. A single comprehensive survey like NFHS offers timelier, consistent data.

Sector Read-Through: Hospitals and Insurance

Private Hospital Chains

• Apollo Hospitals (APOLLOHOSP): Higher institutional deliveries and C-section rates directly boost occupancy and average revenue per bed. Apollo's maternity and paediatric segments account for an estimated 15-20% of revenue. The 2-point gain in institutional deliveries implies a 2-3% volume uplift for this segment.
• Max Healthcare (MAXHEALTH): Similar exposure. The company has been expanding maternity wings in its North India network. The C-section trend supports higher realisations.

Checklist for confirmation:

• Quarterly occupancy rates above 70% for two consecutive quarters.
• Average revenue per patient day (ARPOD) growth of 5%+ year-over-year.
• No adverse regulatory changes in C-section pricing.

Health Insurers

• ICICI Lombard (ICICIGI): Lower stunting and wasting rates reduce long-term morbidity risk. The rise in hypertension and diabetes increases near-term claims. The net effect depends on pricing discipline.
• Star Health (STARHEALTH): As the largest standalone health insurer, Star Health is most exposed to the dual trend. The company's loss ratio has been under pressure; improved health metrics could stabilise it.

What would weaken the thesis:

• If the omitted anaemia data shows persistently high prevalence, maternal health claims could spike.
• If the detailed report reveals higher-than-expected chronic disease rates, insurers may need to raise premiums, dampening volume growth.

Signals That Validate or Invalidate the Hospital Thesis

Confirming Signals

1. Full data release: The government publishes the detailed report on family planning, child health, and women's health within the next 6 months. This would validate the positive trends and reduce policy uncertainty.
2. ICMR anaemia survey: Venous blood sampling results show a decline in anaemia prevalence, confirming the NFHS-6 direction.
3. Hospital earnings: Apollo and Max report 10%+ revenue growth in maternity and paediatric segments in the next two quarters.

Weakening Signals

1. Data controversy: If independent researchers find inconsistencies in NFHS-6 methodology, the entire dataset could be discredited, removing the fundamental support for sector bets.
2. Policy reversal: If the government uses the omitted indicators to justify new price controls on hospital procedures or insurance caps, sector margins would compress.
3. C-section regulation: The 27.2% C-section rate is above the WHO-recommended 10-15%. If regulators impose limits, hospital revenue from deliveries could decline.

Next Catalyst: Full NFHS-6 Report Release

The next concrete catalyst is the release of the detailed NFHS-6 report, expected within 3-6 months. Until then, investors should focus on companies with direct exposure to the confirmed trends: institutional deliveries, child nutrition, and chronic disease diagnostics.

The NFHS-6 data supports a long bias in private hospital chains and diagnostic firms. The omission risk is real manageable if the government delivers the full dataset on schedule. Position sizing should account for the data uncertainty – avoid overweighting sectors that depend on the missing indicators (sanitation, fuel, anaemia).